Epigenetic drugs for Alzheimer's disease: Hopes and challenges

British Journal of Clinical Pharmacology

Volumn 75, Issue 4, 2013, Pages 1154-1155

  Caraci, Filippo ^a   Leggio, Gian Marco ^a   Drago, Filippo ^a   Salomone, Salvatore ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLBUTYRIC ACID; AMYLOID BETA PROTEIN; HISTONE DEACETYLASE INHIBITOR; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT;

ALZHEIMER DISEASE; ARTICLE; COGNITION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EPIGENETICS; HISTONE ACETYLATION; HUMAN; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL;

ALZHEIMER DISEASE; EPIGENESIS, GENETIC; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84875066630     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04443.x     Document Type: Article

References (14)

1. Peedicayil J. Epigenetic drugs for Alzheimer's disease. Br J Clin Pharmacol 2013; 75: 1152-1153.
2. Salomone S, Caraci F, Leggio GM, Fedotova J, Drago F. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br J Clin Pharmacol 2012; 73: 504-517.
3. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov 2012; 11: 384-400.
4. Mastroeni D, Grover A, Delvaux E, Whiteside C, Coleman PD, Rogers J. Epigenetic mechanisms in Alzheimer's disease. Neurobiol Aging 2011; 32: 1161-1180.
5. Cuadrado-Tejedor M, Ricobaraza A, Frechilla D, Franco R, Perez-Mediavilla A, Garcia-Osta A. Chronic mild stress accelerates the onset and progression of the Alzheimer's disease phenotype in Tg2576 mice. J Alzheimers Dis 2012; 28: 567-578.
6. Wilkinson MB, Xiao G, Kumar A, LaPlant Q, Renthal W, Sikder D, Kodadek TJ, Nestler EJ. Imipramine treatment and resiliency exhibit similar chromatin regulation in the mouse nucleus accumbens in depression models. J Neurosci 2009; 29: 7820-7832.
7. Rothman SM, Mattson MP. Adverse stress, hippocampal networks, and Alzheimer's disease. Neuromolecular Med 2010; 12: 56-70.
8. Wilson RS, Arnold SE, Schneider JA, Li Y, Bennett DA. Chronic distress, age-related neuropathology, and late-life dementia. Psychosom Med 2007; 69: 47-53.
9. Guan JS, Haggarty SJ, Giacometti E, Dannenberg JH, Joseph N, Gao J, Nieland TJ, Zhou Y, Wang X, Mazitschek R, Bradner JE, DePinho RA, Jaenisch R, Tsai LH. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 2009; 459: 55-60.
10. Graff J, Rei D, Guan JS, Wang WY, Seo J, Hennig KM, Nieland TJ, Fass DM, Kao PF, Kahn M, Su SC, Samiei A, Joseph N, Haggarty SJ, Delalle I, Tsai LH. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 2012; 483: 222-226.
11. Fischer A, Sananbenesi F, Mungenast A, Tsai LH. Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol Sci 2010; 31: 605-617.
12. Kelly-Sell MJ, Kim YH, Straus S, Benoit B, Harrison C, Sutherland K, Armstrong R, Weng WK, Showe LC, Wysocka M, Rook AH. The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients. Am J Hematol 2012; 87: 354-360.
13. Rossi LE, Avila DE, Spallanzani RG, Ziblat A, Fuertes MB, Lapyckyj L, Croci DO, Rabinovich GA, Domaica CI, Zwirner NW. Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression. J Leukoc Biol 2012; 91: 321-331.
14. Hooker JM, Kim SW, Alexoff D, Xu Y, Shea C, Reid A, Volkow N, Fowler JS. Histone deacetylase inhibitor, MS-275, exhibits poor brain penetration: PK studies of [C]MS-275 using Positron Emission Tomography. ACS Chem Neurosci 2010; 1: 65-73.